SERCA2a gene therapy can improve symptomatic heart failure in δ-sarcoglycan-deficient animals

Human Gene Therapy

Volumn 25, Issue 8, 2014, Pages 694-704

  Bouyon, Sophie ^a   Roussel, Véronique ^a   Fromes, Yves ^a,b  

^a Sorbonne Université   (France)

^b LUNAM UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SARCOGLYCAN; CALCIUM; CARDIOVASCULAR AGENT; HUMAN SARCO ENDOPLASMIC RETICULUM CALCIUM ATPASE 2A; PLASMID VECTOR; POLOXAMER; UNCLASSIFIED DRUG; SARCOGLYCAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOVASCULAR GENE THERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPERIMENTAL HEART FAILURE; FUNCTIONAL STATUS; GENE EXPRESSION; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE RELAXATION; IN VIVO GENE TRANSFER; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REPEATED DRUG DOSE; SARCOGLYCANOPATHY; THERAPY EFFECT; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTIBODY SPECIFICITY; DEFICIENCY; GENE THERAPY; GENETICS; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE PRESSURE; HEMODYNAMICS; HUMAN; MESOCRICETUS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; GENETIC THERAPY; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MESOCRICETUS; MYOCARDIAL CONTRACTION; MYOCARDIUM; ORGAN SPECIFICITY; SARCOGLYCANS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; STROKE VOLUME; VENTRICULAR PRESSURE;

EID: 84906273949     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.132     Document Type: Article

References (44)

1. Alloatti, G., Gallo, M.P., Penna, C., and Levi, R.C. (1995). Properties of cardiac cells from dystrophic mouse. J. Mol. Cell Cardiol. 27, 1775-1779.
2. Bish, L.T., Morine, K., Sleeper, M.M., et al. (2008). Adenoassociated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359-1368.
3. Blain, A.M., and Straub, V.W. (2011). d-Sarcoglycan-deficient muscular dystrophy: From discovery to therapeutic approaches. Skelet. Muscle 1, 13.
4. Duggan, D.J., Manchester, D., Stears, K.P., et al. (1997). Mutations in the d-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Neurogenetics 1, 49-58.
5. Dunn, J.F., and Radda, G.K. (1991). Total ion content of skeletal and cardiac muscle in the mdx mouse dystrophy: Ca2 + is elevated at all ages. J. Neurol. Sci. 103, 226-231.
6. Fauconnier, J., Thireau, J., Reiken, S., et al. (2010). Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 107, 1559-1564.
7. Frank, K.F., Bolck, B., Erdmann, E., and Schwinger, R.H. (2003). Sarcoplasmic reticulum Ca2 + -ATPase modulates cardiac contraction and relaxation. Cardiovasc. Res. 57, 20-27.
8. Fraysse, B., Nagi, S.M., Boher, B., et al. (2010). Ca2 + overload and mitochondrial permeability transition pore activation in living d-sarcoglycan deficient cardiomyocytes. Am. J. Physiol. Cell Physiol. 299, C706-C713.
9. Gaymalov, Z.Z., Yang, Z., Pisarev, V.M., et al. (2009). The effect of the nonionic block copolymer Pluronic P85 on gene expression in mouse muscle and antigen-presenting cells. Biomaterials 30, 1232-1245.
10. Glower, D.D., Spratt, J.A., Snow, N.D., et al. (1985). Linearity of the Frank-Starling relationship in the intact heart: The concept of preload recruitable stroke work. Circulation 71, 994-1009.
11. Holt, K.H., Lim, L.E., Straub, V., et al. (1998). Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using d-sarcoglycan gene transfer. Mol. Cell 1, 841-848.
12. Hoshijima, M., Hayashi, T., Jeon, Y.E., et al. (2010). d- Sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters. Circ. Heart Fail. 4, 89-97.
13. Hunt, S.A. (2005). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46, e1-e82.
14. Hunter, E.G., Hughes, V., and White, J. (1984). Cardiomyopathic hamsters, CHF 146 and CHF 147: A preliminary study. Can. J. Physiol. Pharmacol. 62, 1423-1428.
15. Jessup, M., Greenberg, B., Mancini, D., et al. (2011). Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 +-ATPase in patients with advanced heart failure. Circulation 124, 304-313.
16. Kabanov, A.V., Batrakova, E.V., and Alakhov, V.Y. (2002). Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release 82, 189-212.
17. Kabanov, A., Zhu, J., and Alakhov, V. (2005). Pluronic block copolymers for gene delivery. Adv. Genet. 53PA, 231-261.
18. Kawada, T.,Nakatsuru,Y., Sakamoto, A., et al. (1999).Strain- and age-dependent loss of sarcoglycan complex in cardiomyopathic hamster hearts and its reexpression by d-sarcoglycan gene transfer in vivo. FEBS Lett. 458, 405-408.
19. Kawada, T., Nakazawa, M., Nakauchi, S., et al. (2002). Rescue of hereditary form of dilated cardiomyopathy by rAAVmediated somatic gene therapy: Amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc. Natl. Acad. Sci. U.S.A. 99, 901-906.
20. Li, J., Wang, D., Qian, S., et al. (2003). Efficient and long-term intracardiac gene transfer in d-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther. 10, 1807-1813.
21. Lipskaia, L., Pinet, C., Fromes, Y., et al. (2007). Mutation of dsarcoglycan is associated with Ca2 + -dependent vascular remodeling in the Syrian hamster. Am. J. Pathol. 171, 162-171.
22. Lipskaia, L., Chemaly, E.R., Hadri, L., et al. (2010). Sarcoplasmic reticulum Ca2 + ATPase as a therapeutic target for heart failure. Expert Opin. Biol. Ther. 10, 29-41.
23. Mitsuhashi, S., Saito, N., Watano, K., et al. (2003). Defect of dsarcoglycan gene is responsible for development of dilated cardiomyopathy of a novel hamster strain, J2N-k: Calcineurin/ PP2B activity in the heart of J2N-k hamster. J. Biochem. 134, 269-276.
24. Mongue-Din, H., Salmon, A., Fiszman, M.Y., and Fromes, Y. (2007). Non-invasive restrained ECG recording in conscious small rodents: A new tool for cardiac electrical activity investigation. Pflugers Arch. 454, 165-171.
25. Morita, H., Seidman, J., and Seidman, C.E. (2005). Genetic causes of human heart failure. J. Clin. Invest. 115, 518-526.
26. Netticadan, T., Temsah, R.M., Kawabata, K., and Dhalla, N.S. (2000). Sarcoplasmic reticulum Ca2 + /calmodulin-dependent protein kinase is altered in heart failure. Circ. Res. 86, 596-605.
27. Nigro, V., de Sa Moreira, E., Piluso, G., et al. (1996). Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the d-sarcoglycan gene. Nat. Genet. 14, 195-198.
28. Nigro, V., Okazaki, Y., Belsito, A., et al. (1997). Identification of the Syrian hamster cardiomyopathy gene. Hum. Mol. Genet. 6, 601-607.
29. Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45.
30. Ribadeau Dumas, A., Wisnewsky, C., Boheler, K.R., et al. (1997). The sarco(endo)plasmic reticulum Ca2 +-ATPase gene is regulated at the transcriptional level during compensated left ventricular hypertrophy in the rat. C. R. Acad. Sci. III 320, 963-969.
31. Roques, C., Bouchemal, K., Ponchel, G., et al. (2009a). Parameters affecting organization and transfection efficiency of amphiphilic copolymers/DNA carriers. J. Control. Release 138, 71-77.
32. Roques, C., Fromes, Y., and Fattal, E. (2009b). Hydrosoluble polymers for muscular gene delivery. Eur. J. Pharm. Biopharm. 72, 378-390.
33. Sakamoto, A., Ono, K., Abe, M., et al. (1997). Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, d-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex. Proc. Natl. Acad. Sci. U.S.A. 94, 13873-13878.
34. Sarma, S., Li, N., van Oort, R.J., et al. (2010). Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 107, 13165-13170.
35. Sriadibhatla, S., Yang, Z., Gebhart, C., et al. (2006). Transcriptional activation of gene expression by Pluronic block copolymers in stably and transiently transfected cells. Mol. Ther. 13, 804-813.
36. Straub, V., Duclos, F., Venzke, D.P., et al. (1998). Molecular pathogenesis of muscle degeneration in the d-sarcoglycandeficient hamster. Am. J. Pathol. 153, 1623-1630.
37. Suga, H., and Sagawa, K. (1974). Instantaneous pressure- volume relationships and their ratio in the excised, supported canine left ventricle. Circ. Res. 35, 117-126.
38. Toyo-oka, T., Kawada, T., Xi, H., et al. (2002). Gene therapy prevents disruption of dystrophin-related proteins in a model of hereditary dilated cardiomyopathy in hamsters. Heart Lung Circ. 11, 174-181.
39. Toyoshima, C., Nakasako, M., Nomura, H., and Ogawa, H. (2000). Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature 405, 647-655.
40. Wheeler, M.T., and McNally, E.M. (2003). Sarcoglycans in vascular smooth and striated muscle. Trends Cardiovasc. Med. 13, 238-243.
41. Williams, I.A., and Allen, D.G. (2007). Intracellular calcium handling in ventricular myocytes from mdx mice. Am. J. Physiol. Heart Circ. Physiol. 292, H846-H855.
42. Yang, Z., Sahay, G., Sriadibhatla, S., and Kabanov, A.V. (2008). Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconjug. Chem. 19, 1987-1994.
43. Zhu, T., Zhou, L., Mori, S., et al. (2005). Sustained whole-body functional rescue by systemic delivery of AAV8 vectors in heart failure and muscular dystrophy hamsters. Mol. Ther. 11, S354.
44. Zivcec, M., Safronetz, D., Haddock, E., et al. (2011). Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J. Immunol. Methods 368, 24-35.